Literature Review

In the future, tissue engineering, the reconstruction of organs or organ parts, will produce further and better approaches for the treatment of diseases in widely differing fields. Marred cells or cell structures are thereby renewed so that organs are able to again carry out their original function. One of the next steps will be the growth of whole organs and organ parts. 


Possible and Future Fields of Application

TICEBA BlueMan - Future Fields of Application

Stroke:
Replacement of defective neuronal tissue

Alzheimer's or Parkinson's Disease:
Reproduction of neuronal cells

Multiple Sclerosis:
Replacement of damaged neuronal cells

Heart Attack:
Renewal of damaged heart muscle cells

Cardiac Insufficiency:
Renewal of insufficient heart muscle tissue

Anti-Aging:
Overall regeneration

Muscle Dystrophies:
Regeneration and build-up of musculature

Paraplegia:
Renewal of neural channels

TICEBA - Stem Cells - Possible and Future Fields of Application

 

  • Stroke: Replacement of defective neuronal tissue
  • Heart Attack: Renewal of damaged heart muscle cells
  • Cardiac Insufficiency: Renewal of insufficient heart muscle tissue
  • Alzheimer's or Parkinson's Disease: Reproduction of neuronal cells
  • Muscle Dystrophies: Regeneration and build-up of musculature
  • Paraplegia: Renewal of neural channels
  • Multiple Sclerosis: Replacement of damaged neuronal cells
  • Anti-Aging: Overall regeneration


The described treatments are only a small insight into the diverse future application possibilities of stem cells due to tissue engineering.

Moreover RHEACELL is developing specific drugs based on mesenchymal skin stem cells for the treatment of various diseases.

News
Coronavirus and Mesenchymal Stem Cells

Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus

Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19)

Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus

Article about our study with limbal stem cells

On the website of the Harvard Stem Cell Institute you will find the following news release about the ongoing clinical trial conducted by our daughter company RHEACELL in patients suffering from limbal stem cell deficiency: Restoring vision: A stem cell therapy for cornea regeneration reaches the clinical-trial stage.

Clinical Trial - EB

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and several European competent national regulatory authorities. The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) for the treatment of EB.

Clinical Trial - LSCD

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and the German regulatory authority (Paul Ehrlich Institute). The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) and Fast Track designation from the FDA for the treatment of LSCD.

Safety

In a comprehensive preclinical study program, safety and local tolerability of ABCB5+ MSCs following subcutaneous, intramuscular and intravenous application has been demonstrated (Tappenbeck et al., 2019).

Newsletter